New vaccine aims to train immune system against HPV cancers
NCT ID NCT06319963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine called Lenti-HPV-07 in 72 people with HPV-related throat or cervical cancer. The goal is to see if it is safe and can boost the immune system to fight the cancer. Participants receive the vaccine and are monitored for up to one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florida Cancer Specialists (from Sarah Canon research Institute)
RECRUITINGOrlando, Florida, 32827, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Oklahoma Cancer Specialists and Research Institute, LLC
RECRUITINGTulsa, Oklahoma, 74146, United States
-
Tampa General Hospital
RECRUITINGTampa, Florida, 33606, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Robotic surgery may spare throat cancer patients from chemo and radiation
- Vaccine trains immune system to fight HPV-Positive head and neck tumors
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- Can less radiation be just as good for HPV throat cancer?
- New combo aims to tame HPV throat cancer with fewer side effects